engleski

Molecular monitoring of aml1/eto transcript in aml patients at diagnosis and follow-up by quantitative PCR

The t(8 ; 21) is one of the most common translocations in acute myeloid leukemia (AML) occurring in approximately 20% of adult and 40% of pediatric AML-M2 patients. The result of this translocation is the fusion gene AML1/ETO whose transcripts can be detected by qualitative and quantitative PCR in patients at diagnosis as well as in clinical remission. Using Light Cycler technology, we have analyzed 50 samples of 13 patients who were positive for AML1/ETO transcript at diagnosis by qualitative RT-PCR. For all the patients studied the positive results by qualitative RT-PCR were in agreement with the results obtained by Light Cycler technology. By comparison of two methods we established the cut-off value for aml1/eto transcript:G-6-PDH ratio as 0.27 while the same ratio ranged 0.30-2.35 at diagnosis. Additionally, six patients with t(8 ; 21) AML were studied by quantitative RT-PCR at different time intervals (1-16 months) after therapy was started. We observed a constant decrease in aml1/eto transcript:G-6-PDH ratio from the time of diagnosis (range 1.0-2.35) to below 0.30, 1 to 3 months after the beginning of therapy. We conclude that quantification of residual disease with Real Time RT-PCR is a reliable and sensitive method to monitor the dynamics of disappearance of malignant clone.

molecular monitoring; aml1/eto transcript

nije evidentirano